Research and clinical trials

Based on the title and source metadata, this appears to be a basic science related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a market or business news related to Stem Cell Therapy and Research and clinical trials. The original article is from msn.com.

Cure8 indexed this Crohn's and IBD-related source from finanznachrichten.de. It is tagged for Azathioprine, Steroids, and Immunomodulators. Open the original article for the full details.

Cure8 found this source from newsmax.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Understanding immune cells that help keep gut inflammation in check could point to new ways to predict flares or develop treatments. If low gamma delta IEL levels are confirmed as an early marker, that might help...

Two new Irish-led studies describe non-drug options that could affect how Crohn’s is treated: a dietary regimen for children that may sustain remission, and a surgical technique that may lower post-op relapse and...

Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...

Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture. Open the original article for the full details.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from telegraphherald.com.

Cure8 could only read part of this source from texarkanagazette.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Diet and lifestyle. The original article is from msn.com.

Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

Fatigue is a common, burdensome symptom in Crohn's disease and hard to treat. This study links fatigue severity to differences in brain resting-state connectivity, suggesting brain–gut interactions may play a role.

This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.

Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...

A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...

This study suggests viral exposures—specifically Epstein–Barr virus—might be associated with later development of Crohn’s disease, which could help researchers study disease triggers. If confirmed, such findings might...

If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...

A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from uk.finance.yahoo.com.

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Research and clinical trials. Open the original article for the full details.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from specialtypharmacycontinuum.com.

If you have moderate to severe Crohn’s disease, this study suggests some patients who don’t respond to initial risankizumab induction may still benefit from a longer induction period, including improved symptoms and...

An FDA approval means guselkumab (Tremfya) is now an approved treatment option for adults with moderate-to-severe Crohn’s disease, including a unique option for fully subcutaneous induction. This may expand choices for...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...

This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.

The study identifies a possible early immune-cell change that may trigger Crohn’s disease-like inflammation and suggests a potential biomarker (loss of γδ IELs) and therapeutic direction. For people with IBD, this could...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...

This study identifies a specific immune cell (γδ intraepithelial lymphocytes) that may fail before Crohn’s disease appears, which could help researchers develop early biomarkers or new therapies to prevent inflammation.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may...

Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 found this source from science.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...

A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.